The Latest
-
Mario Tama via Getty Images
3 major patent losses this year — and a key strategy to fill the gaps
Despite promising pipelines, most new launches are missing sales targets, forcing pharmas to rethink sales strategies.
-
Stock via Getty Images
Why FDA’s CRL release could open the door to lawsuits against pharma
In a push for “radical transparency” the FDA released 200 CRLs for drugs that were later approved — some of which are now public for the first time.
-
Mario Tama / Staff via Getty Images
J&J accelerates past Stelara’s fall with better-than-expected portfolio growth
Stelara is faltering due to biosimilar entries, but J&J execs demonstrate they were ready to fill the gap all along.
-
Stock via Getty Images
FDA invites more data from abroad — with a wary eye on China
The FDA approved four drugs last year without any U.S. trial participants, but has maintained a tougher stance on China, even as it grows into an R&D powerhouse.
-
Michael M. Santiago via Getty Images
Biotech IPO momentum gained steam last year, but market ‘turmoil’ has slowed the train again
The IPO market is a mixed bag in 2025, with some signs of life but several headwinds keeping activity relatively low.
-
Stock via Getty Images
Q&ANeed a DTC platform? Here’s how one company built its own.
Currax Pharmaceuticals was ahead of the curve when it set up a direct access platform for its obesity med.
-
Jason Doiy via Getty Images
With Verona deal, Merck wagers on strength of lung drug’s patents
The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make good on the deal, other secondary patents will need to hold up.
-
Jan Sonnenmair via Getty Images
Early measles drug R&D kicks into gear as U.S. records record outbreak
Several companies have announced preclinical efforts to develop the first-ever measles treatment.
-
Getty Images via Getty Images
Pricing watchdog will take on the rising cost of drugs at launch
ICER’s upcoming report could shed light on how the launch price of newly approved drugs affects overall cost and access from a patient perspective.
-
Stock via Getty Images
First 90 DaysAs its cancer vaccine moves through the clinic, Transgene sets sights on manufacturing
Simone Steiner recently joined the French company to set the stage for launch.
-
Andrew Harnik via Getty Images
Trump says ‘very high’ pharmaceutical tariffs coming soon
While Trump indicated drug levies would be as high as 200%, he added that pharma firms would first be given time to bring manufacturing back to the U.S.
-
Getty Images via Getty Images
Is biopharma dealmaking getting hot again?
With pharma’s finger on the M&A button, three of the biggest deals of the year are breadcrumbs that could lead to a full-on resurgence.
-
Stock via Getty Images
The MEK effect on cancer — a slow and steady approach to drug resistance
Immuneering Corporation’s investigational MEK inhibitor aims to outpace cancer while reducing resistance and side effects.
-
stock via Getty Images
GLP-1 roadblocks: Discontinuation rates soar as insurers clamp down
As more drugmakers aim for the lucrative weight loss market, patient challenges linger.
-
E+ via Getty Images
Can China sustain a surge in oncology drug innovation?
The country’s trajectory may get a boost from anticipated results of a Keytruda rival’s U.S. trials.
-
iStock via Getty Images
AI’s ‘massive transition’ in biopharma shapes leadership mindsets — tension and all
The AI revolution is driving tension between new technology and the traditional approaches in drugmaking. Biopharma leaders are trying to navigate those turbulent waters.
-
Stock via Getty Images
First 90 DaysA biopharma bolsters patient centricity and trial diversity goals through newly created role
Ardelyx’s newly minted chief patient officer is infusing patient experiences into every element of the business.
-
Andrew Harnik via Getty Images
FDA’s new mission to speed drug reviews
FDA Commissioner Dr. Marty Makary is leading a handful of controversial new initiatives to make the drug review process more streamlined.
-
Justin Sullivan via Getty Images
3 of the year’s most notable FDA nods
The agency has granted approvals steadily in the first part of the year, including nods for several breakthrough therapies.
-
hxdbzxy via Getty Images
Top pharma and biotech conferences in the second half of 2025 and beyond
Mark your calendars for the most important industry conferences in the second half of 2025 and into next year.
Updated June 27, 2025 -
Grandbrothers via Getty Images
Biopharma is on edge about NIH funding cuts and what the future holds for research
Proposed cuts to public funding for early science have led to an outcry in scientific circles. For biopharma leaders, the effects are still up in the air.
-
Elijah Nouvelage via Getty Images
CDC panel, newly remade by RFK Jr., questions vaccine evidence
New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at other established shots, like those for measles and hepatitis B.
-
Stock via Getty Images
After myriad failures, a new wave of ALS drugs approaches
Several drugmakers anticipate trial results and FDA submissions in 2025 and 2026, including some still overcoming past failures.
-
Permission granted by Parabilis
Q&AHow a Big Pharma veteran looks to stand out in biotech as a unique ‘drug hunter’
J&J’s former head of R&D, now CEO of Parabilis Medicines, aims to remain above the biotech fray by taking on unique targets from which others have steered clear.
-
Stock via Getty Images
Biogen scores Cannes Festival win with dark humored campaign
The company’s unique campaign for a rare, terminal illness nabbed millions of views and a spot on the main stage at the Cannes Lions Festival of Creativity.
